메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Xinyu Wan (Shanghai Jiao Tong University School of Medicine Shanghai China) Xiaomin Yang (Shanghai Jiao Tong University School of Medicine Shanghai China) Fan Yang (Shanghai Jiao Tong University School of Medicine Shanghai China) Tianyi Wang (Shanghai Jiao Tong University School of Medicine Shanghai China) Lixia Ding (Shanghai Jiao Tong University School of Medicine Shanghai China) Lili Song (Shanghai Jiao Tong University School of Medicine Shanghai China) Yan Miao (Shanghai Jiao Tong University School of Medicine Shanghai China) Xiang Wang (Shanghai Jiao Tong University School of Medicine Shanghai China) Yani Ma (Shanghai Jiao Tong University School of Medicine Shanghai China) Chengjuan Luo (Shanghai Jiao Tong University School of Medicine Shanghai China) Jingyan Tang (Shanghai Jiao Tong University School of Medicine Shanghai China) Longjun Gu (Shanghai Jiao Tong University School of Medicine Shanghai China) Jing Chen (Shanghai Jiao Tong University School of Medicine Shanghai China) Yanjing Tang (Shanghai Jiao Tong University School of Medicine Shanghai China) Jun Lu (Children’s Hospital of Soochow University Jiangsu China) Benshang Li (Shanghai Jiao Tong University School of Medicine Shanghai China)
저널정보
대한암학회 Cancer Research and Treatment Cancer Research and Treatment 제54권 제3호
발행연도
2022.7
수록면
917 - 925 (9page)
DOI
10.4143/crt.2021.399

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
PurposeAnti-CD19 chimeric antigen receptor T-cell immunotherapy (19CAR-T) has achieved impressive clinical results in adult and pediatric relapsed/refractory (r/r) B-lineage acute lymphoblastic leukemia (B-ALL). However, the application and effect of CAR-T therapy in B-ALL patients with extramedullary relapse are rarely issued even disqualified in some clinical trials. Here, we examined the efficacy of 19CAR-T in patients with both bone marrow and extramedullary involvement.Materials and MethodsCAR-T cells were generated by transfection of primary human T lymphocytes with a lentiviral vector expressing anti-CD19 single chain antibody fragments (scFvs) with the cytoplasmic domains of 4-1BB and CD3ζ, and used to infuse patients diagnosed as having r/r B-ALL with extramedullary origination. Clinical responses were evaluated by the use of bone marrow aspiration, imaging, and flow cytometry. ResultsEight patients received 19CAR-T infusion and all attained complete remission (CR). Only one patient was bridged to hematopoietic stem cell transplantation (HSCT). Although three patients relapsed after infusion, they received 19/22CAR-T infusion sequentially and attained a second remission. To date, five patients are in continuous CR and all eight patients are still alive. The mean follow-up time was 21.9 months, while the 24-month estimated event-free survival is 51.4%. Conclusion19CAR-T therapy can lead to clinical remission for extramedullary relapsed pediatric B-ALL patients. However, the problem of CD19+ relapses after CAR-T remained to be solved. For patients relapsing after CAR-T, a second CAR-T therapy creates another opportunity for remission for subsequent HSCT.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0